Opioid agonist therapy in and beyond the COVID-19 pandemic: A descriptive policy analysis across Canadian jurisdictions

BACKGROUND: The COVID-19 pandemic prompted widespread rapid changes to opioid agonist therapy (OAT) policy in Canada, reshaping how care was delivered to people with opioid use disorder. To better understand how OAT policy changes varied across jurisdictions, we conducted a comparative policy analysis identifying federal, provincial, and territorial OAT policy changes that occurred during and after the COVID-19 pandemic. METHODS: Policy documents (n = 88) were sourced from grey literature, targeted website searches, and recommendations from relevant knowledge experts conducted between June-July 2024 and May-July 2025. A combined content and thematic analysis approach was employed to organize identified policy changes (n = 300) into eight policy areas: expanded prescribing permissions, take-home dosing, witnessed dosing, medication delivery, urine drug screening, virtual care, slow-release oral morphine, and injectable OAT. RESULTS: Across jurisdictions, policies governing OAT evolved considerably during and after the COVID-19 pandemic, though the scope and durability of these changes varied significantly. Federal exemptions enabled policy changes, specifically in expanding prescribing authorities and medication delivery. These authorities were translated differently across regions spanning narrow renewal-focused roles to broader clinical discretion. Policies addressing take-home dosing and monitoring requirements showed the greatest divergence, with provinces such as Ontario and Nova Scotia adopting more permissive approaches, while Saskatchewan and Manitoba maintained more restrictive, structured approaches. CONCLUSIONS: Pandemic circumstances supported the implementation of OAT policy changes that increased flexibility and permissiveness of OAT delivery. However, uneven implementation risks the perpetuation of geographic and equity-based disparities, emphasizing the need for coordinated and equity-focused OAT policy.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Policy
Published
2026-11-13
DOI
https://doi.org/10.1016/j.drugpo.2026.105601
Primary Topic
Opioid Use Disorder Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Opioid agonist therapy in and beyond the COVID-19 pandemic: A descriptive policy analysis across Canadian jurisdictions

Ginette Poulin, Nikki Bozinoff, Graham Macdonald, Kellia Chiu et al.
2 links
International Journal of Drug Policy
Opioid Use Disorder Treatment
article

Opioid agonist therapy in and beyond the COVID-19 pandemic: A descriptive policy analysis across Canadian jurisdictions

Ginette Poulin, Nikki Bozinoff, Graham Macdonald, Kellia Chiu, Andrea Bowra, Abhimanyu Sud, Stefanie Materniak, Ross E. G. Upshur, Gillian Kolla, Lara L. Nixon, Sheena Aislinn Taha, Tate HubkaRao, Kelsey MacIntosh, Sean Patenaude, Kelsey Dumont, Samuel Hickcox, Sofie Naeem, Mikhail Torban
article en

Abstract

BACKGROUND: The COVID-19 pandemic prompted widespread rapid changes to opioid agonist therapy (OAT) policy in Canada, reshaping how care was delivered to people with opioid use disorder. To better understand how OAT policy changes varied across jurisdictions, we conducted a comparative policy analysis identifying federal, provincial, and territorial OAT policy changes that occurred during and after the COVID-19 pandemic. METHODS: Policy documents (n = 88) were sourced from grey literature, targeted website searches, and recommendations from relevant knowledge experts conducted between June-July 2024 and May-July 2025. A combined content and thematic analysis approach was employed to organize identified policy changes (n = 300) into eight policy areas: expanded prescribing permissions, take-home dosing, witnessed dosing, medication delivery, urine drug screening, virtual care, slow-release oral morphine, and injectable OAT. RESULTS: Across jurisdictions, policies governing OAT evolved considerably during and after the COVID-19 pandemic, though the scope and durability of these changes varied significantly. Federal exemptions enabled policy changes, specifically in expanding prescribing authorities and medication delivery. These authorities were translated differently across regions spanning narrow renewal-focused roles to broader clinical discretion. Policies addressing take-home dosing and monitoring requirements showed the greatest divergence, with provinces such as Ontario and Nova Scotia adopting more permissive approaches, while Saskatchewan and Manitoba maintained more restrictive, structured approaches. CONCLUSIONS: Pandemic circumstances supported the implementation of OAT policy changes that increased flexibility and permissiveness of OAT delivery. However, uneven implementation risks the perpetuation of geographic and equity-based disparities, emphasizing the need for coordinated and equity-focused OAT policy.

International Journal of Drug PolicyVol. 158
The University of Sydney (AU), Memorial University of Newfoundland (CA), Ministry of Health (CA), Centre for Addiction and Mental Health (CA), University of Calgary (CA), University of the Fraser Valley (CA), University of Toronto (CA), University of Victoria (CA), Saskatchewan Health Authority (CA), Canadian Centre on Substance Use and Addiction (CA), Canadian Public Health Association (CA), Horizon Health Network (CA), Nova Scotia Health Authority (CA), Humber River Regional Hospital (CA), Government of British Columbia (CA), Canadian Institute for Substance Use Research (CA), Campbell Family Mental Health Research Institute (CA), University of Manitoba (CA), NOSM University (CA)
Canadian Institutes of Health Research
Good health and well-being
Opioid Use Disorder Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon